Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CC-94676 in men with progressive metastatic castration resistant prostate cancer.
For more information, please contact the recruiting sites directly. If there is no contact information, please email: Clinical.Trials@bms.com. The first line of the email MUST contain the NCT # and Site #.
The safety and efficacy of investigational agents and/or investigational uses or combination of agents approved for other indications have not been established. There is no guarantee that investigational agents or regimens will receive health authority approval or become commercially available in any country for uses under investigation.
Log in below to access your account on BMS Science or Bolder Science. If you have an existing Bolder Science account, please use your login credentials for that account here.
Please enter your email address.
You will receive a link to create a new password via email.
Use the form below to create one account that will be used across both BMS Science and Bolder Science. Clinical trials that you save on either site will be shown together on your dashboard on Bolder Science. If you already have an account, you can log in here.